Market Place
Sourcing Support
Spago Nanomedical Interim Report January-September 2024
06 Nov 2024 //
ACCESSWIRE
Spago Nanomedical Appoints Nomination Committee For AGM 2025
21 Oct 2024 //
ACCESSWIRE
Spago Nanomedical in New Phase with Focus on the Tumorad Program
01 Oct 2024 //
ACCESSWIRE
Spago Nanomedical`s Tumorad-01 Study Continues After First Group Treatment
27 Aug 2024 //
ACCESSWIRE
Spago Nanomedical Interim Report January-June 2024
21 Aug 2024 //
ACCESSWIRE
Spago To12 Exercise Intentions: Owner Board Mgmt Declarations Received
23 May 2024 //
ACCESSWIRE
Spago Nanomedical Provides an Update on Tumorad-01 - Trial Proceeds as Planned
20 May 2024 //
ACCESSWIRE
Spago Nanomedical TO12 Warrant Exercise Period Commences
17 May 2024 //
ACCESSWIRE
Spago Nanomedical Publishes the Annual Report for 2023
16 May 2024 //
ACCESSWIRE
Notice To Annual General Meeting of Spago Nanomedical AB (Publ)
06 May 2024 //
ACCESSWIRE
Spago Nanomedical Interim Report January-March 2024
02 May 2024 //
ACCESSWIRE
Spago Nanomedical Reports Favorable Data in Breast Cancer Model with Tumorad
24 Apr 2024 //
ACCESSWIRE
Spago Nanomedical Strengthens Management with Head of CMC & Supply
16 Apr 2024 //
ACCESSWIRE
Spago Nanomedical Year-end Report January-December, 2023
07 Feb 2024 //
ACCESSWIRE
Spago Nanomedical Presents at Redeye`s Fight Cancer Event on January 24
18 Jan 2024 //
ACCESSWIRE
Spago Nano Proceeds to the Next Dose Level in the Phase I/IIa Study Tumorad-01
10 Jan 2024 //
ACCESSWIRE
Spago Reports Positive Data from Phase IIa Study SPAGOPIX-02
15 Dec 2023 //
ACCESSWIRE
First Patient Dosed in Spago`s Phase I/IIa Study within Tumorad Program
07 Dec 2023 //
ACCESSWIRE
Nomination Committee Appointed for Spago Nano’s Annual General Meeting 2024
14 Nov 2023 //
ACCESSWIRE
Spago Nanomedical Interim Report January-September 2023
03 Nov 2023 //
ACCESSWIRE
Bulletin from the Extraordinary General Meeting of Spago Nanomedical
31 Oct 2023 //
ACCESSWIRE
Spago Nanomedical applies for extended patent protection for Tumorad(R)
24 Oct 2023 //
ACCESSWIRE
Spago Receives Approval to Initiate the Clinical Phase I/IIa study with Tumorad
19 Oct 2023 //
ACCESSWIRE
Notice to the Extraordinary General Meeting of Spago Nanomedical AB (publ)
05 Oct 2023 //
ACCESSWIRE
Spago Nanomedical interim report January-June 2023
31 Jul 2023 //
ACCESSWIRE
Spago Nanomedical Updates on the Clinical Phase IIa Study SPAGOPIX-02
28 Jun 2023 //
ACCESSWIRE
Spago Nanomedical Strengthens Tumorad® by Establishment of Advisory Board
13 Jun 2023 //
ACCESSWIRE
Spago has Submitted Application to Start Tumorad(R) Clinical Phase I/IIa Study
23 May 2023 //
ACCESSWIRE
Spago Nanomedical Interim Report January-March 2023
09 May 2023 //
ACCESSWIRE
Presentation of Spago Nanomedical`s Clinical pH IIa Study in Endometriosis
04 May 2023 //
ACCESSWIRE
Spago Nanomedical Publishes the Annual Report for 2022
29 Mar 2023 //
ACCESSWIRE
Spago Nanomedical Year-end Report January-December, 2022
02 Feb 2023 //
ACCESSWIRE
Spago Nanomedical Terminates Liquidity Guarantee
27 Dec 2022 //
ACCESSWIRE
First Patient Dosed in Spago Nanomedical’s Endometriosis Phase IIa Study
08 Dec 2022 //
ACCESSWIRE
Spago Nanomedical Initiates Trial with SpagoPix in Endometriosis SPAGOPIX-01
05 Dec 2022 //
ACCESSWIRE
Nomination Committee Appointed for the 2023 Annual Meeting in Spago Nanomedical
20 Oct 2022 //
ACCESSWIRE
Spago Nanomedical gets SpagoPix Abstract Accepted at Breast Cancer Conference
21 Sep 2022 //
ACCESSWIRE
Extended SpagoPix Patent Protection in USA
02 May 2022 //
ACCESSWIRE
Spago Nanomedical Presents its Q1 Report and Provides Company Update
20 Apr 2022 //
ACCESSWIRE
Notice to Annual General Meeting of Spago Nanomedical AB (publ)
11 Apr 2022 //
ACCESSWIRE
Spago Nanomedical Publishes the Annual Report for 2021
23 Feb 2022 //
ACCESSWIRE
